A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial

Sricharoenchai, Sirintip; Sirivichayakul, Chukiat; Chokephaibulkit, Kulkanya; Pitisuttithum, Punnee; Dhitavat, Jittima; Pitisuthitham, Arom; Phongsamart, Wanatpreeya; Boonnak, Kobporn; Lapphra, Keswadee; Sabmee, Yupa; Wittawatmongkol, Orasri; Chinwangso, Pailinrut; Poredi, Indrajeet Kumar; Pétré, Jean; Thái, Phạm Hồng; Viviani, Simonetta

doi:10.1016/s1473-3099(17)30612-6

Cited by 23 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We are concerned by the transient increased of PT-specific antibody responses in aPprimed vaccinees, as FHA is not specific of Bordetella pertussis and most strain do no longer express pertactin. Neutralizing antibody responses to r-PT boosting were significantly lower than reported in Thai wP-primed adolescents [28]. This could be accounted for by differences in ethnicity, pertussis exposure, number of previous immunizations, influence of Td co-administration, etc.…”

Section: Discussionmentioning

confidence: 75%

“…A Phase I/II randomized controlled trial (RCT) including wP-primed Thai adults indicated similar safety but significantly higher PT seroresponses to the BNA rPT-containing recombinant aP vaccine (r-aP) than to the cdPT-containing Tdap (cd/Tdap) comparator [27]. This was subsequently confirmed in 450 wP-primed Thai adolescents [28]. Here, we compared the reactogenicity and immunogenicity of BNA r-aP (given with tetanus-diphtheria, r-aP+Td) and cd/Tdap to boost aP-primed Swiss adolescents.…”

Section: Introductionmentioning

confidence: 91%

“…Secondary endpoints Anti-PT and anti-FHA IgG antibody concentrations were measured by standardized enzyme linked immunosorbent assays (ELISA) at the Center for Vaccinology (Geneva) using plates coated with BNA's purified rPT or FHA as described [27]. Responses to BNA rPT strongly correlate (R 2 =0.9837, not shown) to those assessed with native PT (nPT), as recommended for use in PT-specific assays [28,29,31,32]. The limit of detection was defined at 1 IU/ml.…”

Section: Immunogenicity Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

Blanchard-Rohner

Chatzis

Chinwangso³

et al. 2018

Clinical Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 91%

Section: Immunogenicity Assessmentmentioning

confidence: 99%

See 1 more Smart Citation

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

Blanchard-Rohner

Chatzis

Chinwangso³

et al. 2018

Clinical Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

“…Over a third of our participants perceived the lack of a pertussis-only vaccine to be a barrier to some extent, with a resultant lower likelihood of performing the vaccination. Availability of such a vaccine as recently licensed in Thailand [59] and studied in Switzerland [60] would therefore likely additionally increase acceptance and coverage [61].…”

Section: Discussionmentioning

confidence: 99%

Influenza and pertussis vaccination during pregnancy – attitudes, practices and barriers in gynaecological practices in Germany

Böhm

Röbl-Mathieu

Scheele³

et al. 2019

BMC Health Serv Res

View full text Add to dashboard Cite

Background In Germany, antenatal influenza vaccination is recommended since 2010, but uptake remains low. Several countries recently introduced antenatal pertussis vaccination, which is currently under consideration in Germany. We conducted a survey among gynaecologists on attitudes, practices and barriers regarding influenza and pertussis vaccination during pregnancy. Methods Gynaecologists were invited to complete a pre-tested, 24-item questionnaire published in the German Professional Association of Gynaecologists’ journal in September 2017 within 2 months. Associations between variables were examined using Chi-Squared, Fischer’s Exact or t-tests. Variables associated with gynaecologists’ self-reported implementation of vaccination in pregnant women were identified using univariate and multivariate logistic regression analyses. Results Of 867 participants (response 11%), 91.4 and 59.4% reported currently vaccinating pregnant women against influenza and pertussis, respectively. Gynaecologists who reported obtaining annual influenza vaccination and actively informing their patients about these vaccinations were significantly more likely to vaccinate pregnant women against influenza (96.5% vs. 65.7 and 95.1% vs. 62.2%) and pertussis (63.1% vs. 44.3 and 82.4% vs. 12.9%). Performing influenza vaccination was least likely among gynaecologists who perceived logistical difficulties as a vaccination barrier (35.9%), while pertussis vaccination was least likely if the lacking official recommendation (32.0%), logistical difficulties (27.1%), safety concerns (17.5%) and limited vaccine effectiveness (11.1%) were perceived as barriers. Of participants not yet vaccinating pregnant women against pertussis, 86.5% reported they would follow an official recommendation. Including vaccination recommendations in the maternity record (95.2%) and informing the public (88.7%) and health care professionals (86.6%) were considered the most suitable measures to achieve high pertussis vaccination coverage. Conclusions The large proportion reporting performance of influenza vaccination during pregnancy and high acceptance of a potential recommendation for pertussis vaccination reflected positive attitudes towards vaccination among participants. However, factors associated with failure to vaccinate may be more prevalent among non-participants. Results suggest that gynaecologists’ confidence in vaccination is crucial for implementing vaccination in pregnancy. Thus, doubts on vaccine effectiveness and safety should be allayed among gynaecologists and pregnant women via various communication channels, and solutions for logistical barriers sought. Including antenatal vaccination recommendations in the maternity record would serve as an important reminder for both groups. Electronic supplementary material The online version of this article (10.1186/s12913-019-4437-y) contains supplementary material, which is avail...

show abstract

“…Sricharoenchai et al [6] berichten in mehreren Publikationen über die Entwicklung eines neuen Pertussis-Impfstoffs in Thailand, der in Studien eine bessere Immuno-genität und Persistenz der Pertussis-spezifischen Impfantwort besitzt.…”

Section: Neuer Pertussis-impfstoffunclassified

Neue Entwicklungen bei Impfstoffen für Kinder und Jugendliche

Knuf

Zepp

2018

Drug Res (Stuttg)

View full text Add to dashboard Cite

A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial

Cited by 23 publications

References 25 publications

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial

Influenza and pertussis vaccination during pregnancy – attitudes, practices and barriers in gynaecological practices in Germany

Neue Entwicklungen bei Impfstoffen für Kinder und Jugendliche

Contact Info

Product

Resources

About